2/7/2026

Janusmed kön och genus

Janusmed kön och genus – Orkambi

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Ivakaftor

Ivakaftor

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. EMA. Kalydeco. CHMP Assessment report; 2012 http://goo.gl/vIoApt

  2. Socialstyrelsen. Sällsynta hälsotillstånd - cystisk fribros. Socialstyrelsen [www]. [updated 2022-01-21, cited 2025-12-19].

  3. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol. 2010;45(10):959-65.

  4. Holtrop M, Cosmich S, Lee M, Keller A, Jain R. Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis. Chest. 2024;166(5):951-962.

  5. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.

  6. Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):.

  7. EMA Assessment report. Orkambi (lumacaftor/ivacaftor). Published 01/12/2015.

  8. Kaftrio Assessment report. EMA [www]. [updated 2021-03-25, cited 2022-07-21].

  9. Wang A, Lee M, Keller A, Jian S, Lowe K, Finklea JD et al. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024;23(1):91-98.

  10. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819.

  11. Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L et al. Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor. J Pediatr. 2024;274:114176.

  12. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666.

  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. EMA. Kalydeco. CHMP Assessment report; 2012 http://goo.gl/vIoApt
  2. Socialstyrelsen. Sällsynta hälsotillstånd - cystisk fribros. Socialstyrelsen [www]. [updated 2022-01-21, cited 2025-12-19].
  3. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol. 2010;45(10):959-65.
  4. Holtrop M, Cosmich S, Lee M, Keller A, Jain R. Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis. Chest. 2024;166(5):951-962.
  5. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.
  6. Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):.
  7. EMA Assessment report. Orkambi (lumacaftor/ivacaftor). Published 01/12/2015.
  8. Kaftrio Assessment report. EMA [www]. [updated 2021-03-25, cited 2022-07-21].
  9. Wang A, Lee M, Keller A, Jian S, Lowe K, Finklea JD et al. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024;23(1):91-98.
  10. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819.
  11. Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L et al. Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor. J Pediatr. 2024;274:114176.
  12. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666.
  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]
C C
C C

Lumakaftor

Lumakaftor

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Assessment report - Orkambi (lumacaftor/ivacaftor). European Medicines Agency (EMA) [www]. [cited 2025-12-19].

  2. Socialstyrelsen. Sällsynta hälsotillstånd - cystisk fribros. Socialstyrelsen [www]. [updated 2022-01-21, cited 2025-12-19].

  3. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol. 2010;45(10):959-65.

  4. Holtrop M, Cosmich S, Lee M, Keller A, Jain R. Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis. Chest. 2024;166(5):951-962.

  5. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.

  6. Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):.

  7. Aalbers BL, Hofland RW, Bronsveld I, de Winter-de Groot KM, Arets HGM, de Kiviet AC et al. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. J Cyst Fibros. 2021;20(1):e7-e11.

  8. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666.

  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Assessment report - Orkambi (lumacaftor/ivacaftor). European Medicines Agency (EMA) [www]. [cited 2025-12-19].
  2. Socialstyrelsen. Sällsynta hälsotillstånd - cystisk fribros. Socialstyrelsen [www]. [updated 2022-01-21, cited 2025-12-19].
  3. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol. 2010;45(10):959-65.
  4. Holtrop M, Cosmich S, Lee M, Keller A, Jain R. Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis. Chest. 2024;166(5):951-962.
  5. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.
  6. Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res. 2021;7(1):.
  7. Aalbers BL, Hofland RW, Bronsveld I, de Winter-de Groot KM, Arets HGM, de Kiviet AC et al. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. J Cyst Fibros. 2021;20(1):e7-e11.
  8. Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662-1666.
  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]